DERMATOLOGICAL MANIFESTATIONS OF POLYCYSTIC OVARY SYNDROME

Autores

  • Gabriela de Souza Martins UNIFAN
  • Joaquim Adriano Antunes de Almeida UNIFAN
  • Ana Paula Mendes Macedo Trigueiro UNIFAN
  • Daiana Bettanin de Melo Alexandrino UNIFAN
  • Fernanda de Queiroz Albuquerque FMNE
  • Júlia Ferreira Junqueira UNIFAN
  • Guilherme Augusto Santana Silva UNIFAN
  • Thais Heloan de Souza UNIFAN
  • Gabriela de Freitas Ribeiro UNIFAN
  • Thiago Arruda Prado Cavalcante UNIFAN
  • Kenneth Candeira Sampaio UNIFAN
  • Guilherme Guimarães de Paula Poleto UNIFAN
  • Renata de Paula Ribeiro Dechichi UNIFAN
  • Ariel Ferreira Paula UNIFAN
  • Geziany Vieira dos Santos Cunha UNIFAN
  • Vanessa Fontana Porfirio Ribas UNIFAN

DOI:

https://doi.org/10.36557/2674-8169.2024v6n2p2180-2193

Palavras-chave:

Resumo

Polycystic ovary syndrome (PCOS) is one of the most common endocrine conditions in women of reproductive age, characterized by hormonal imbalances, ovulatory dysfunction, and multiple ovarian cysts. In addition to gynecological symptoms, PCOS can also present significant dermatological manifestations, which affect not only the appearance, but also the quality of life of patients. These manifestations include hirsutism, acne, alopecia and skin pigmentation, among others. Understanding the relationship between PCOS and its dermatological manifestations is crucial for early diagnosis and adequate management of the condition. Objective: To analyze and synthesize recent scientific literature on dermatological manifestations associated with polycystic ovary syndrome, highlighting its prevalence, clinical characteristics and therapeutic approaches. Methodology: The systematic review was conducted in accordance with PRISMA guidelines. Searches were carried out in the PubMed, Scielo and Web of Science databases, limited to articles published in the last 10 years, using the descriptors "polycystic ovary syndrome", "dermatological manifestations", "hirsutism", "acne", "alopecia" . The inclusion criteria were original human studies, in English or Portuguese, that investigated dermatological manifestations in patients with PCOS. Exclusion criteria were animal studies, case reports and narrative reviews. Results: The analysis of the selected studies revealed a high prevalence of dermatological manifestations in patients with PCOS, with hirsutism and acne being the most common. Factors such as insulin resistance and hyperandrogenism play an important role in the development of these manifestations. Several therapeutic approaches, including hormonal agents and insulin modulators, have been investigated for the management of these symptoms. Conclusion: This review highlights the importance of identifying and adequately treating dermatological manifestations in PCOS, aiming not only to improve aesthetics, but also the quality of life and overall health of patients. Early recognition of these symptoms can lead to effective interventions and better long-term clinical outcomes.

Downloads

Não há dados estatísticos.

Referências

Sekhon AK, Zergham AS, Tserenpil G, Mebasher A, Malik BH. The Association Between Polycystic Ovary Syndrome and Its Dermatological Manifestations. Cureus. 2020 Feb 3;12(2):e6855. doi: 10.7759/cureus.6855.

Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017 Mar-Apr;8(2):104-110. doi: 10.4103/2229-5178.202275.

Aguilar Medina DA, Cazarín J, Magaña M. Spironolactone in dermatology. Dermatol Ther. 2022 May;35(5):e15321. doi: 10.1111/dth.15321.

Hong JS, Kwon HH, Park SY, Jung JY, Yoon JY, Min S, Choi YM, Suh DH. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):42-7. doi: 10.1111/jdv.12432. Epub 2014 Mar 14.

Holzer G, Straßegger B, Volc-Platzer B. Hautmanifestationen beim metabolischen Syndrom [Cutaneous manifestations of metabolic syndrome]. Hautarzt. 2016 Dec;67(12):982-988. German. doi: 10.1007/s00105-016-3891-2.

Aljefri YE, Alahmadi RA, Alajmi RS, Alkhamisi TA, Maaddawi HA, Alraddadi AA, Alamri AM. Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center. Cureus. 2021 Dec 22;13(12):e20593. doi: 10.7759/cureus.20593.

Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi Yarandi R, Saei Ghare Naz M, Carmina E. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a systemic review and meta-analysis. Gynecol Endocrinol. 2021 May;37(5):392-405. doi: 10.1080/09513590.2020.1859474.

Feng JG, Guo Y, Ma LA, Xing J, Sun RF, Zhu W. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in northern China. J Cosmet Dermatol. 2018 Jun;17(3):511-517. doi: 10.1111/jocd.12387.

Radu AM, Carsote M, Dumitrascu MC, Sandru F. Acanthosis Nigricans: Pointer of Endocrine Entities. Diagnostics (Basel). 2022 Oct 17;12(10):2519. doi: 10.3390/diagnostics12102519.

Sandru F, Petca A, Dumitrascu MC, Petca RC, Carsote M. Peutz-Jeghers syndrome: Skin manifestations and endocrine anomalies (Review). Exp Ther Med. 2021 Dec;22(6):1387. doi: 10.3892/etm.2021.10823.

Benson J, Severn C, Hudnut-Beumler J, Simon SL, Abramson N, Shomaker LB, Gulley LD, Taylor A, Kelsey MM, Nadeau KJ, Zeitler PS, Pyle L, Cree-Green M. Depression in Girls With Obesity and Polycystic Ovary Syndrome and/or Type 2 Diabetes. Can J Diabetes. 2020 Aug;44(6):507-513. doi: 10.1016/j.jcjd.2020.05.015.

Patil AD, Vaidya RA, Begum S, Chauhan SL, Mukherjee S, Kokate PP, Joshi BN. An integrated multidisciplinary model of care for addressing comorbidities beyond reproductive health among women with polycystic ovary syndrome in India. Indian J Med Res 2022 Sep;156(3):449-458. doi: 10.4103/ijmr.IJMR_2497_19.

Weghuber D, Barrientos-Pérez M, Kovarenko M. Youth-Onset Type 2 Diabetes Manifestations in other Specialties: Its Many Disguises. Ann Nutr Metab. 2019;74(4):339-347. doi: 10.1159/000500234.

Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertile Sterile. 2014 Apr;101(4):1129-34. doi: 10.1016/j.fertnstert.2014.01.003.

Amer RI, Yassin GE, Mohamed RA, Fayez AM. Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Experimentally Induced Hirsutism in Rats. AAPS PharmSciTech. 2021 Jul 13;22(5):204. doi: 10.1208/s12249-021-02003-z.

Downloads

Publicado

2024-02-26

Como Citar

Martins , G. de S., Almeida, J. A. A. de, Trigueiro, A. P. M. M., Alexandrino, D. B. de M., Albuquerque, F. de Q., Junqueira , J. F., Silva , G. A. S., Souza , T. H. de, Ribeiro, G. de F., Cavalcante , T. A. P., Sampaio, K. C., Poleto , G. G. de P., Dechichi, R. de P. R., Paula, A. F., Cunha , G. V. dos S., & Ribas, V. F. P. (2024). DERMATOLOGICAL MANIFESTATIONS OF POLYCYSTIC OVARY SYNDROME. Brazilian Journal of Implantology and Health Sciences, 6(2), 2180–2193. https://doi.org/10.36557/2674-8169.2024v6n2p2180-2193

Edição

Seção

Revisão de Literatura